Jos Immerzeel
Papers
1
Total Citations
459
H-Index
1
About
Jos Immerzeel is a leading figure in prostate cancer outcomes research, with a focus on comparative effectiveness of radical therapies. His seminal 2012 study, "Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group," has garnered 459 citations, underscoring its impact. Immerzeel’s major contribution lies in synthesizing data across treatment modalities—such as surgery, radiation, and brachytherapy—to evaluate PSA-free survival as a sensitive endpoint for treatment success. This work addressed a critical gap: the lack of comparative studies using the most sensitive measurement tools, providing clinicians with evidence-based insights for risk-stratified decision-making. By highlighting variations in outcomes across low, intermediate, and high-risk groups, his research has shaped clinical guidelines and informed patient counseling. Immerzeel’s dedication to rigorous meta-analytic methods and collaborative efforts through the Prostate Cancer Results Study Group has advanced the field, making his work essential reading for researchers and clinicians striving to optimize prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1